Skip to main content
. 2013 Apr 25;49(1):31–37. doi: 10.4068/cmj.2013.49.1.31

Fig. 2.

Fig. 2

Percentage change in HbA1C, fasting glucose, and fasting insulin levels. The control and rosuvastatin treatment groups did not show significant changes in HbA1C levels (mean change, 3.0±10.1% vs. -1.3±12.7%; p=0.33), fasting glucose levels (-1.3±18.0% vs. 2.5±24.1%; p=0.69), or fasting insulin levels (mean change, 5.2±70.5% vs. 22.6±133.2%; p=0.27) from baseline.